Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray), a nasal spray approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years of age and older. There are currently no approved nasal sprays available […]